课题基金 / 基金详情

Evaluating the gene delivery potential of E1L4-deficient adenovirus vectors

Evaluating the gene delivery potential of E1L4-deficient adenovirus vectors
评估 E1L4 缺陷腺病毒载体的基因传递潜力
批准号:
BB/E014550/1
负责人:
Keith Leppard
金额:
$45.25万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2007
资助国家:
英国
项目状态:
已结题
起止时间:
2007 至 --

项目摘要

项目成果

Keith Leppard的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The aim of this project is to evaluate the performance of a new version of the adenovirus gene delivery system that has been widely considered as a way of achieving gene therapy in people. Adenoviruses, which naturally infect people, can be made incapable of growing and causing disease by removing parts of their genome DNA, and then foreign gene sequences can be added in their place to create a gene delivery vector. When the vector infects a cell, the foreign gene is efficiently taken into the cell but, ideally, no further events of the infectious cycle occur. Instead, the foreign gene becomes operative in the cell and has a beneficial effect. However, many earlier versions of adenovirus vectors suffered from two related problems: the gene delivery effect did not last very long and powerful immune responses were generated to viral proteins made from the so-called 'late' genes that had not been removed from the genomes of these vectors. Adenovirus late genes provide proteins that are essential for the vector to be grown in the laboratory. If you take the late genes out of the vector, you cannot grow the vector particles that you need to use in therapy unless you provide the proteins in a different way. The two options are to mix the vector with a second virus that still has these late genes, so it can help the vector to grow, or to make special cells that contain the missing genes and to use these to grow the vector. In the first case you end up with a mixture from which you have to separate out the vector particles that you want, which is difficult on a large scale, while in the second case, persuading cells to make all these proteins in the large amounts needed has so far been impossible. We have been working on a new way to prevent the production of these late viral proteins when a vector is used, that works without actually removing all the genes. This means that the genes can still be used to provide the necessary proteins when growing the vector in the laboratory. The trick is to remove the genes for just two late proteins, which we have discovered turn on the production of all the others. When these two proteins are provided the vector grows well but otherwise, none of the late genes it carries will work. We have made cells that will make these two key proteins 'on demand' / the cells cannot be asked to make them all the time because they harm the cells / and have used them to grow a virus that has the two genes removed. Now we want to find out how this deleted virus behaves when used for gene delivery. First of all, we need to study its basic properties, such as how easy it is to grow and how stable its particles are. Then, we are planning to use it to study the delivery of a test gene into cells and tissues, to find out how long the gene stays around and keeps working.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1128/jvi.01924-13
发表时间: 2013-11
期刊: Journal of virology
影响因子: 5.4
作者: [Wright J, Leppard KN]
通讯作者: Leppard KN
DOI: 10.1128/jvi.00683-15
发表时间: 2015-07
期刊: Journal of virology
影响因子: 5.4
作者: [Wright J, Atwan Z, Morris SJ, Leppard KN]
通讯作者: Leppard KN
DOI: 10.1128/mbio.02184-15
发表时间: 2016-01-26
期刊: mBio
影响因子: 6.4
作者: [Bridges RG, Sohn SY, Wright J, Leppard KN, Hearing P]
通讯作者: Hearing P
Generation of cell lines to complement adenovirus vectors using recombination-mediated cassette exchange.
使用重组介导的盒式交换生成细胞系以补充腺病毒载体。
DOI: 10.1186/1472-6750-10-92
发表时间: 2010-12-23
期刊: BMC biotechnology
影响因子: 3.5
作者: [Morris SJ, Farley DC, Leppard KN]
通讯作者: Leppard KN
Defining and exploiting the role of PML protein in innate immune responses to pathogens
  • 批准号:
    MR/P022901/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $54.86万
  • 财政年份:
    2017
  • 负责人:
    Keith Leppard
  • 依托单位:
国内基金
海外基金
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    周海波
  • 依托单位:
Pik3r2基因突变在家族内侧颞叶癫痫中的作用及发病机制研究
  • 批准号:
    82371454
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    郝勇
  • 依托单位:
22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
  • 批准号:
    82370906
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    代杰文
  • 依托单位:
发展基因编码的荧光探针揭示趋化因子CXCL10的时空动态及其调控机制